Related Experiment Video
Updated: Jul 9, 2025
Isolation and Transplantation of Different Aged Murine Thymic Grafts.
Published on: May 13, 2015
What makes a pediatric or young adult patient an appropriate transplant candidate?
Monica S Thakar1,2, Mohamed L Sorror1,3
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Insights
The youth-nonmalignant HCT-Comorbidity Index (CI) better predicts nonrelapse mortality (NRM) risk in children with chronic granulomatous disease undergoing hematopoietic cell transplantation (HCT). This revised index accounts for factors like fungal infections and mechanical ventilation.
Area of Science:
- Pediatric Hematology
- Immunology
- Transplantation Medicine
Background:
- Chronic granulomatous disease (CGD) poses significant health challenges, including recurrent infections and failure to thrive.
- Allogeneic hematopoietic cell transplantation (HCT) is a potential curative therapy for CGD.
- Assessing pre-transplant comorbidity is crucial for predicting outcomes in pediatric HCT.
Purpose of the Study:
- To evaluate the applicability of the HCT-Comorbidity Index (CI) in a pediatric CGD patient.
- To determine the risk of nonrelapse mortality (NRM) for a 3-year-old CGD patient considering HCT.
- To highlight the limitations of the original HCT-CI and the utility of the youth-nonmalignant HCT-CI.
Main Methods:
- Case review of a 3-year-old child with CGD.
- Calculation of HCT-CI using the original index and the validated youth-nonmalignant HCT-CI.
- Assessment of comorbidities including Aspergillus fumigatus pneumonia, sepsis, mechanical ventilation, failure to thrive, and developmental delay.
Main Results:
- The original HCT-CI yielded a negligible NRM risk score (0).
- The youth-nonmalignant HCT-CI resulted in a score of 5, indicating a significantly increased NRM risk.
- Specific factors contributing to the higher score included prior mechanical ventilation (+3), fungal infection (+1), and underweight status (+1).
Conclusions:
- The youth-nonmalignant HCT-CI provides a more accurate risk assessment for pediatric patients with non-malignant conditions like CGD.
- HCT was recommended for the patient, but with realistic counseling regarding NRM.
- Developmental delay's prognostic value in this context requires further investigation.
Abstract:
A 3-year-old child with chronic granulomatous disease was brought to the transplant clinic by his parents. The patient has a history of Aspergillus fumigatus pneumonia, which required mechanical ventilation, and sepsis, resulting in several intensive care stays. He has failure to thrive and developmental delay. His parents are seeking guidance whether allogeneic hematopoietic cell transplantation (HCT) is a reasonable treatment option given concerns about his upfront major health limitations. Based on the original HCT-Comorbidity Index (CI), this child's risk for nonrelapse mortality (NRM) would be negligible with a score of 0. With use of the validated youth-nonmalignant HCT-CI, the score increases to 5, due to prior mechanical ventilation (+3), history of fungal infection (+1), and being underweight (+1), with at least 2-fold increase in risk of NRM. The role of developmental delay is unclear and not currently validated to prognosticate survival. While HCT was ultimately recommended in this case, the family was counseled to have a more realistic sense of NRM risk.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...